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Abstract
More women with cystic fibrosis (CF) now reach reproductive age and wish to become pregnant. Although women with CF
have reduced fertility, many of them can become mothers. A pregnancy ought to be carefully planned since serveral studies have
shown that pregnancy is well tolerated if good medical care is provided, and the CF woman is in a stable good condition. A
short review of the implications of pregnancy for women with CF is presented. A suggested schedule for pregnant women with
CF is given.  2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Women with cystic fibrosis (CF) have reduced fertil-
ity, in part related to tenacious cervical mucus w1x and
ovulation disturbances w2x. However, in a retrospective
study in Sweden and Norway, we have found a sponta-
neous pregnancy rate of over 50% w3x. It is therefore of
importance that CF women, who do not wish to become
pregnant, are using contraceptive methods. It has been
debated as to whether oral contraceptives are suitable
for women with CF w4,5x. So far, no studies have proven
them to be harmful, and thus they can be recommended
for CF women without other complications, such as
severe liver disease w4,5x.
A pregnancy ought to be carefully planned, since
several studies have shown that pregnancy is well
tolerated if good medical care is provided and the CF
woman is in a good, stable condition w6–11x. Pre-
pregnancy lung function and body weight are useful
indicators of outcome for both mother and child w6x.
Problems arise when women with moderate disease have
to be counseled, since there are no absolute levels of
physiological, functional and nutritional impairment for
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a successful pregnancy. We do know that women with
moderate to severe lung disease (Forced expiratory
volume 1 second (FEV1) -50%), colonization with
Burkholderia cepacia, pancreatic insufficiency, poor
nutrition and diabetes mellitus produce more pre-term
infants and do worse themselves w6–11x. However, we
also know that pregnancy per se does not appear to
modify the course of the disease w9,11x.
So far, the experience concerning lung transplantation
and pregnancy is limited. There are no known side
effects of the immunosuppressive medicines on the fetus,
and the transplants appear to be unaffected by pregnan-
cies w12x.
Certain physiological changes in the body during
normal pregnancy have to be taken into account when
caring for pregnant CF women.
2. Physiological changes in the body during pregnan-
cy in relation to CF
2.1. Respiratory
Normal pregnancy is a state of compensated respira-
tory alkalosis. Effective exchange of CO from the fetus2
to the mother requires the PCO to be higher in the2
fetus than in the mother. Progesterone stimulates the
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respiratory centers in the brain to produce hyperventi-
lation early in pregnancy. Secondary to this, a majority
(60–70%) of normal healthy women complain of dysp-
nea during pregnancy w13,14x. Inspiratory capacity sig-
nificantly increases, due to flaring of the lower ribs and
widening of the rib cage. This might become a problem
for CF patients, who are very tense in their thoracic
musculature. Relaxation of smooth muscles in the trach-
eobronchial tree secondary to hormonal changes decreas-
es total pulmonary resistance in late pregnancy. This
might be beneficial for the patients who have more
obstructive airway disease. However, at the end of
pregnancy, residual volume decreases secondary to ele-
vation of the diaphragm. This may create regions with
low ventilation–perfusion ratios, which adversely affect
gas exchange w13,14x. All these physiological changes
can cause a CF woman with poor lung function to
deteriorate during pregnancy. Even so, non-invasive
ventilatory support has been used successfully in such
cases w15x.
2.2. Cardiovascular system
The cardiac output increases by approximately 40%
at week 20, and the blood volume increases by approx-
imately 40%, with a peak at week 30 secondary to new
placental circulation, as well as general vasodilatation
w16x. Additional increases in blood volume and cardiac
output are observed during labor and delivery. Pulmo-
nary hypertension is considered to be a contraindication
to pregnancy due to this increase in cardiac work w17x.
2.3. Pancreas
In healthy women, the number of B-cells and size of
Langerhan islets increase during pregnancy w18x. It is
not known if this also happens in women with CF and
pancreatic insufficiency (PI). Glucose provides the
major fuel requirement for the fetus. Placental hormones
create a state of ‘insulin resistance’, with increased
levels of insulin associated with decreased cellular
response w19x. Blood glucose levels should be carefully
monitored in CF women, since they might more readily
develop gestational diabetes. In one study of pregnant
women with CF, the prevalence of gestational diabetes
was 14% w11x, which is higher than in the general
population w20,21x.
2.4. Liver
The gall bladder empties more slowly during preg-
nancy, and a certain degree of cholestasis is considered
physiological during pregnancy w22x. This can cause
problems for CF patients, since they may already have
impaired bile secretion w23x.
2.5. Gastrointestinal tract
Decreased motility and increased absorption of water
and salt in the gastrointestinal (GI) tract is noted during
normal pregnancy. This may give rise to constipation in
healthy individuals w22x. Pregnant CF women may suffer
more from this condition, since many already have
problems with the GI tract w24x. CF women may also
suffer from increased gastroesophageal reflux commonly
observed during pregnancy w22,24x.
2.6. Nutrition
A pregnancy demands approximately 300 extra kcaly
day w25x. A weight gain during pregnancy above 11 kg
is recommended to reassure good nutrition for the
woman and the fetus w26x. Many patients with CF have
problems with this extra energy requirement. However,
it is necessary to provide a pregnant CF woman with
all the nutritional support available, since it is known
that many of the CF women who fail to adequately gain
weight may give birth prematurely w3,6,26x. It is also
very important to remember that deficiency of essential
fatty acids (EFAs) is observed in healthy women during
pregnancy and lactation w27x. This may aggravate the
already deranged EFA status of CF women, and thereby
worsen CF symptoms w28x. It should also be remem-
bered that certain minerals and vitamins, such as iron
and folic acid, need to be provided during pregnancy
for optimal fetal health w29x.
2.7. Immunity
The balance in the immune system changes from
cellular to humoral response in order to protect the fetus
during a pregnancy w30x. This is probably the reason
why pregnant women are considered to be at greater
risk of certain infections w31x. Some autoimmune dis-
eases, such as multiple sclerosis and rheumatoid arthrith-
is, may benefit from this, while other autoimmune
diseases may worsen w30,32,33x. So far, we do not know
how this change in immunity affects CF, but it does not
appear to worsen the disease w9,11x. Elevated cortisol
levels that are observed during pregnancy w13,34x might
be beneficial, since there are indications that CF is a
‘proinflammatory state’ w35x, and many CF patients also
have bronchial hyper-reactivity w36x. It might also be
that the altered immunological state during pregnancy,
with an increase in certain ‘anti-inflammatory’ cytoki-
nes, such as interleukin 10 w37x, could positively mod-
ulate the CF disease, since studies have shown that
IL-10 is down-regulated in CF w38–40x.
2.8. Pharmacology
Physiological changes during pregnancy change the
pharmacokinetics of many drugs. The increase in mater-
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nal plasma volume creates a larger volume of distribu-
tion, and more rapid renal clearance is observed
secondary to increased filtration rate w22,41,42x. Plasma
binding may change, as well as intestinal absorption.
Hepatic metabolism is usually not affected w22x. So far,
we have too little knowledge on the use of recombinant
DNAase during pregnancy, and thus this inhalation
should be avoided. Tetracycline may cause discoloration
of deciduous teeth, and ciprofloxacin should be avoided,
since this drug has caused irreversible arthropathy in
animal studies w41x. Non-steroidal anti-inflammatory
drugs may cause constriction of the ductus arteriosus
and predispose to necrotizing enterocolitis if given late
in pregnancy w43x. So far, aminoglycosides have often
been avoided during pregnancy in CF women due to
fear of fetal ototoxicity. There are no studies showing
this complication in humans w41–43x. However, it would
appear prudent not to administer this therapy during the
first trimester. Most other CF drugs, including antibiot-
ics, can be used with relative safety during pregnancy
w41–43x. This is important to remember, since CF
women might experience exacerbation of their disease
during pregnancy. No pharmacological studies on preg-
nant CF women have so far been performed, and thus
we do not know if pregnant CF women need higher or
lower doses of antibiotics. Considering the changes in
pharmacokinetics among healthy pregnant individuals,
CF women probably need higher doses of antibiotics
during pregnancy w41–43x.
2.9. Delivery
Vaginal delivery with optimal pain relief and oxygen
supply is recommended for both healthy women and for
women with CF and cardiac disease w13,16,26x. Bron-
chodilators should be used during delivery if necessary.
Cesarean section should only be used for obstetric
indications. If cesarean section is necessary, emphasis
should be placed on rapid mobilization and active
physiotherapy postoperatively.
2.10. Lactation
Deficiency of EFAs are observed in healthy women
during pregnancy and lactation w27x. This is important
to remember when deciding if breastfeeding should be
encouraged for a CF woman who might already have
nutritional problems w44x. The breast milk from CF
women usually supplies the energy needs of the nursing
infants w44x. Analysis of breastmilk has shown normal
protein and sodium content, but somewhat lower levels
of linoleic acid w45,46x. Breastfeeding should be encour-
aged if it is beneficial for both the mother and the child.
3. Conclusion
Since many physiological changes occur in the body
during pregnancy, good teamwork between dedicated
health workers is necessary to provide optimal care for
pregnant CF women.
Appendix A: Suggested visit schedule pregnant CF
women
– Monthly visits CF clinic as soon as pregnancy
diagnosed.
– Visit every other week in end of pregnancy.
– Close contact between CF team members and OBy
GYN clinic.
Initial visit
1. Visit with CF clinician for clinical status, including
heartylung auscultation, blood pressure, weight and
spirometry.
2. Sputum culture
3. Blood test (infection parameters, blood glucose, vita-
min AyE, iron and essential fatty acid levels)
4. Echocardiography as needed.
5. Visit with physiotherapist, dietician, social workery
psychologist and special OByGYN clinic.
Following visits
1. As above.
2. Change of oral vitamin supplements to increase intake
of folic acid and iron during pregnancy.
3. Generous use of antibiotics when signs of low-grade
infection.
4. Generous use of nutritional supplements to obtain
adequate calorie intake.
5. Physiotherapy.
Post-delivery and during lactation
– Close contact as above.
References
w1x Kopito LE, Kosasky HJ, Shwachman H. Water and electrolytes
in cervical mucus from patients with cystic fibrosis. Fertil
Steril 1973;24:512–6.
w2x Johannesson M, Csemiczky G, Landgren B-M, Hjelte L,
Gottlieb C. Female patients with cystic fibrosis suffer from
reproductive endocrinological disorders despite good clinical
status. Hum Reprod 1998;13:2092–7.
w3x Oedagaard I, Hallberg K, Stray-Pedersen B, Haanes O, Stor-
roesten O, Johannesson M. Fertility rate and outcome of
pregnancies among women with cystic fibrosis in Norway and
Sweden. Ped Pulmon 1999;Suppl 19:. Abstract 604.
w4x Fizpatrick SB, Stokes DC, Rosenstein BJ, Terry P, Hubbard
VS. Use of oral contraceptives in women with cystic fibrosis.
Chest 1984;86:863–7.
w5x Orme M, Back DJ. Oral contraceptive steroids — pharmaco-
logical issues of interest to the prescribing physician. Adv
Contraception 1991;7:325–31.
12 M. Johannesson / Journal of Cystic Fibrosis 1 (2002) 9–12
w6x Kotloff RM, FitzSimmons SC, Fiel SB. Fertility and pregnancy
in patients with cystic fibrosis. Clin Chest Med 1992;13:623–
35.
w7x Edenborough FP, Stableforth DE, Webb AK, Mackenzie WE,
Smith DL. Outcome of pregnancy in women with cystic
fibrosis. Thorax 1995;50:170–4.
w8x Edenborough FP, Mackenzie WE, Stableforth DE. The outcome
of 72 pregnancies in 55 women with cystic fibrosis in the
United Kingdom 1997–1996. Br J Obstet Gyn
2000;107(2):254–61.
w9x FitzSimmons SC, Fitzpatrick S, Thompson B, et al. A longi-
tudinal study of the effects of pregnancy on 325 women with
cystic fibrosis. Pediatr Pulmon 1996;Suppl 13:99–101. 10th
North American Cystic Fibrosis Conference.
w10x Jankelson D, Robinson M, Parsons S, Torzillo P, Peat B, Bye
P. Cystic fibrosis and pregnancy. Aust NZ J Obstet Gynaecol
1998;38:180–4.
w11x Gilljam M, Antoniou M, Shin J, Dupuis A, Corey M, Tullis
E. Pregnancy in cystic fibrosis. Fetal and maternal outcome.
Chest 2000;118(1):85–91.
w12x Zirbes J, Wielinski CL. Case report of pregnancy course of
CF lung transplant recipient. Ped Pulmon 1995;Suppl 13:. 9th
North American Cystic Fibrosis Conference, abstract 287.
w13x Elkus R, Popovich J. Respiratory physiology in pregnancy.
Clin Chest Med 1992;13:555–65.
w14x Weinberger SE, Weiss SC, Cohen WR, Woodrow Weiss J,
Sott Johnson T. State of the art: pregnancy and the lung. Am
Rev Respir Dis 1980;121:559–81.
w15x Butler JA, Esmond GM, Mickelsons C, Empey DW. Pregnancy
assisted by nasal intermittent positive-pressure ventilation in a
patient with cystic fibrosis. J R Soc Med 1997;90:222–3.
w16x Mogensen L. Cardiac considerations related to pregnancy. J
Internal Med 1994;235:383–5.
w17x McAnulty JH, Metcalfe J, Ueland K. Cardiovascular disease.
In: Burrow GN, Ferris TF, editors. Medical Complications
During Pregnancy. 3rd. Medical Complications During Preg-
nancy. Philadelphia: WB Saunders, 1988.
w18x Puavilai G, Drogny EC, Domont LA, Bauma G. Insulin
receptors and insulin resistance in human pregnancy: evidence
for a post receptor defect in insulin action. J Clin Endo Metab
1982;54:247–53.
w19x Speroff L, Glass RH, Kase NG. The endocrinology of preg-
nancy. In: Speroff L, Glass RH, Kase NG, editors. Clinical
Gynecological Endocrinology and Infertility. 5th edition. Clin-
ical Gynecological Endocrinology and Infertility. Baltimore,
USA: Williams & Wilkins, 1994.
w20x Pausi K, McFarland KF. Management of diabetes in pregnancy.
Am Fam Physician 1997;55:2731–8.
w21x Coustan D. Screening and testing for gestational diabetes.
Obstet Gynecol Clin North Am 1996;23:126–36.
w22x McFayden IR. Maternal changes in normal pregnancy. In:
Turnbull SA, Chamberlain G, editors. Obstretics. Obstretics.
Livingstone, Edinburgh, London, Melbourne and New York:
Churchill, 1989.
w23x Lindblad A. Liver Disease in Cystic Fibrosis. Sweden: Goth-
enburg University, 1998. PhD thesis.
w24x Eggermont E. Gastrointestinal manifestations in cystic fibrosis.
Eur J Gastrol Hepatol 1996;8:731–8.
w25x King JC, Butte NF, Bronstein MN, Kopp LE, Lindquist SA.
Energy metabolism during pregnancy: influence of maternal
energy status. Am J Clin Nutr 1994;59(Suppl):439S–445S.
w26x Hilman BC, Aitken ML, Constantinescu M. Pregnancy in
patients with cystic fibrosis. Clin Obstet Gynecol 1996;39:70–
86.
w27x Holman RT, Johnson SB, Ogburn PL. Deficiency of essential
fatty acids and membrane fluidity during pregnancy and lac-
tation. Proc Natl Acad Sci USA 1991;88:4835–9.
w28x Strandvik B. Relation between essential fatty acid metabolism
and gastrointestinal symptoms in cystic fibrosis. Acta Paediatr
Scand 1989;363(Suppl):58–65.
w29x Colie CF. Medications in pregnancy. Curr Opin Obstet Gynecol
1996;8:398–402.
w30x Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional
cytokine interactions in the maternal-fetal relationship: is suc-
cessful pregnancy a TH2 phenomenon? Immunol Today
1993;14:353–6.
w31x Brabin BJ. Epidemiology of infection in pregnancy. Rev
Infectious Dis 1985;7:579–603.
w32x Da Silva JAP, Spector TD. The role of pregnancy in the course
and aetiology of rheumatoid arthritis. Clin Rheumatol
1992;11:189–94.
w33x Duquette P, Girard M. Hormonal factors in susceptibility to
multiple sclerosis. Curr Opin Neurol Neurosurg 1993;6:195–
201.
w34x Nolten WE, Rueckert PA. Elevated free-cortisol index in
pregnancy: possible regulatory mechanisms. Am J Obstet
Gynecol 1981;139:492–8.
w35x Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches
DW. Early pulmonary inflammation in infants with cystic
fibrosis. Am J Respir Crit Care Med 1995;151:1075–82.
w36x Bisgaard H, Pedersen SS, Nielsen KG, et al. Controlled trial
of inhaled budesonide in patients with cystic fibrosis and
chronic bronchopulmonary Pseudomonas aeruginosa infection.
Am J Respir Crit Care Med 1997;156:1190–6.
w37x Szekeres-Bartho J, Wegmann TG. A progesterone-dependent
immunomodulatory protein alter the Th1yTh2 balance. J
Reprod Immunol 1996;31:81–95.
w38x Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory
cytokines in cystic fibrosis lungs. Am J Resp Crit Care Med
1995;152:2111–8.
w39x Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilliard
JB, Berger M. Normal bronchial epithelial cells constitutively
produce the anti-inflammatory cytokine interleukin-10, which
is down-regulated in cystic fibrosis. Am J Respir Cell Mol
Biol 1995;13:257–61.
w40x Moss RB, Bocian RC, Hsu Y-P, et al. Reduced IL-10 secretion
by CD T lymphocytes expressing mutant cystic fibrosis4q
transmembrane conductance regulator. Clin Exp Immunol
1996;106:374–88.
w41x Dashe JS, Gilstrap LC. Antibiotic use in pregnancy. Obstet
Gyn Clin North Am 1997;24:617–29.
w42x Edwards MS. Antibacterial therapy in pregnancy and neonates.
Clin Perinatol 1997;24:251–66.
w43x Koren G, Pasuszak A, Ito S. Drugs in pregnancy. N Engl J
Med 1998;338:1128–37.
w44x Kent NE, Farquharson DF. Cystic fibrosis in pregnancy. Can
Med Assoc J 1993;149:809–13.
w45x Alpert SE, Cormier AD. Normal electrolyte and protein content
in milk from mothers with cystic fibrosis: an explanation for
the initial report of elevated milk sodium concentration. J
Pediatr 1983;102:77–80.
w46x Bitman J, Hamosh M, Wood DL, Freed LM, Hamosh P. Lipid
composition of milk from mothers with cystic fibrosis. Pedi-
atrics 1987;80:927–32.
